IRB approval on track as scheduledNext step is obtaining all regulatory approvals, followed by site initiation visitVELDONA significantly increases unstimulated...
CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosingDose-dependent exposure was observed with evidence of...
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company...
In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of...
KIRYAT ONO, ISRAEL and EDISON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a...
– Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer...
DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present...
Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunitiesSOUTH SAN FRANCISCO, Calif., Nov. 11, 2024...
Institutional Investment of £600,000Hemogenyx Pharmaceuticals Secures £0.6m for Phase I Clinical Trials LONDON, UNITED KINGDOM / ACCESSWIRE / November 11,...
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical...
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS...
Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected...
Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort...
Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish...
Two oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics’ TCR-T...
TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that...
SINGAPORE, Nov. 8, 2024 /PRNewswire/ -- HistoIndex, a pioneering leader in artificial intelligence (AI) and stain-free digital pathology, will present...
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--$BFLY #POCUS--Butterfly Network, Inc. (“Butterfly”) (NYSE: BFLY), a digital health company transforming care through the...
Winners received prestigious award in recognition of latest innovations in advancement in life sciences NEW YORK, Nov. 8, 2024 /PRNewswire/...
Facility significantly increases future financial and operational flexibilityUp to $200M available, with $30 million drawn at close and additional $80...